Maze Therapeutics valued at $690.4 million in lukewarm Nasdaq debut
Maze Therapeutics became the latest drug developer to list in New York on Friday, with its shares rising nearly 1% in their debut, giving the company a valuation of $690.37 million. The muted market ...
Investor's Business Daily on MSN46m
Dow Jones Futures: Trump Tariffs Start But More Coming; Amazon, Google, Palantir Earnings Due
Trump tariffs vs. Canada, Mexico and China start Saturday, with Friday's news capping a wild market week. Amazon, Google and Palantir earnings loom.